Lanthionine Ketimine Ethyl Ester Accelerates Remyelination in a Mouse Model of Multiple Sclerosis

Although over 20 disease modifying therapies are approved to treat Multiple Sclerosis (MS), these do not increase remyelination of demyelinated axons or mitigate axon damage. Previous studies showed that lanthionine ketenamine ethyl ester (LKE) reduces clinical signs in the experimental autoimmune e...

Descripción completa

Detalles Bibliográficos
Autores principales: Dupree, Jeffrey L., Paez, Pablo M., Tiwari-Woodruff, Seema K., Denton, Travis T., Hensley, Kenneth, Angeliu, Christina G., Boullerne, Anne I., Kalinin, Sergey, Egge, Sophia, Cheli, Veronica T., Denaroso, Giancarlo, Atkinson, Kelley C., Feri, Micah, Feinstein, Douglas L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272172/
https://www.ncbi.nlm.nih.gov/pubmed/35791633
http://dx.doi.org/10.1177/17590914221112352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272172/
https://www.ncbi.nlm.nih.gov/pubmed/35791633
http://dx.doi.org/10.1177/17590914221112352

Ejemplares similares